Compulsory Licensing of Pharmaceutical Products & Access to Essential Medicines in Developing Countries

1583 visningar
uppladdat: 2005-01-01
Inactive member

Inactive member

Nedanstående innehåll är skapat av Mimers Brunns besökare. Kommentera arbete
For many years pharmaceutical patents and their impact on prices have been at the centre of the international debate over insufficient access to lifesaving HIV/AIDS medicines in developing countries. The conflict has largely revolved around the implementation of an intellectual property system in the developing world, subsequent the adaptation of the TRIPS Agreement, which has made a 20 year pharmaceutical patent protection mandatory for these countries and consequently contributed to high drug prices for patented medicines as well as limited the use of generic drugs.Developing countries, where patents are already in place, have sought to reduce high drug prices by making use of compulsory licensing, a safeguarding practice allowing the production or importation of a generic medicine without the consent of the patent holder. Compulsory licences are allowed under the TRIPS Agreement, but disagreements about the conditions, under which compulsory licences are available for ‘essential medicines’, have restricted their use. A definition of the extent to which compulsory licensees can export generic drugs to developing countries unable to manufacture their own has been missing, but on 30 August 2003 the WTO announced that it had resolved this problem by lifting the TRIPS Agreement’s restrictions on exports and permitting exports of drugs produced under a compulsory license as an exception to a patent right. The main question is whether the compulsory licensing system as prescribed in the recent Decision is an ample means of improving access to patented AIDS medicines in the developing world.By means of legal and economic reasoning this master thesis argues that the 30 August Decision on lifting TRIPS’ restrictions on exports of patented pharmaceuticals produced under compulsory licences provides complex and uncertain rules, rendering an unreliable employment of compulsory licensing. It is desirable that further recommendations are given on which generic producing companies should be awarded compulsory licences and also on which premises. In reality, the debate about compulsory licensing is part of a much wider structural problem in development policy. The solution to the inaccessibility problem requir...

...läs fortsättningen genom att logga in dig.

Medlemskap krävs

För att komma åt allt innehåll på Mimers Brunn måste du vara medlem och inloggad.
Kontot skapar du endast via facebook.

Källor för arbetet

Saknas

Kommentera arbetet: Compulsory Licensing of Pharmaceutical Products & Access to Essential Medicines in Developing Countries

 
Tack för din kommentar! Ladda om sidan för att se den. ×
Det verkar som att du glömde skriva något ×
Du måste vara inloggad för att kunna kommentera. ×
Något verkar ha gått fel med din kommentar, försök igen! ×

Kommentarer på arbetet

Inga kommentarer än :(

Liknande arbeten

Källhänvisning

Inactive member [2005-01-01]   Compulsory Licensing of Pharmaceutical Products & Access to Essential Medicines in Developing Countries
Mimers Brunn [Online]. https://mimersbrunn.se/article?id=18505 [2024-04-29]

Rapportera det här arbetet

Är det något du ogillar med arbetet? Rapportera
Vad är problemet?



Mimers Brunns personal granskar flaggade arbeten kontinuerligt för att upptäcka om något strider mot riktlinjerna för webbplatsen. Arbeten som inte följer riktlinjerna tas bort och upprepade överträdelser kan leda till att användarens konto avslutas.
Din rapportering har mottagits, tack så mycket. ×
Du måste vara inloggad för att kunna rapportera arbeten. ×
Något verkar ha gått fel med din rapportering, försök igen. ×
Det verkar som om du har glömt något att specificera ×
Du har redan rapporterat det här arbetet. Vi gör vårt bästa för att så snabbt som möjligt granska arbetet. ×